NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

學科招聘/保留服務市場:第二版

Patient Recruitment and Retention Services Market (2nd Edition) by Therapeutic Areas (Cardiovascular Diseases, Oncological Disorders, Infectious Diseases, CNS Disorders, Respiratory Disorders, Hematological Disorders and Others),

出版商 Roots Analysis 商品編碼 1008223
出版日期 內容資訊 英文 365 Pages
商品交期: 最快1-2個工作天內
價格
學科招聘/保留服務市場:第二版 Patient Recruitment and Retention Services Market (2nd Edition) by Therapeutic Areas (Cardiovascular Diseases, Oncological Disorders, Infectious Diseases, CNS Disorders, Respiratory Disorders, Hematological Disorders and Others),
出版日期: 2021年03月31日內容資訊: 英文 365 Pages
簡介

多年來,隨著各種數字數據生成、管理和營銷解決方案的出現,受試者招募和保留策略發生了重大變化。然而,沒有多少製藥公司擁有開發所需功能和有效使用解決方案所需的專業知識和資源。因此,外包成為了一種流行的學科招聘和保留的運營模式。

在本報告中,我們將研究和分析學科招聘和保留服務市場,關注主要公司的當前場景和未來機會,並提供市場狀況、公司分析、市場預測等系統信息。它提供.

目錄

第一章前言

第 2 章執行摘要

第 3 章介紹

第四章主題外展方法

  • 章節概述
  • 主題推廣方法

第五章學科招聘/保留服務提供商的市場競爭狀況

  • 章節概述
  • 學科招聘/保留服務提供商:整體市場情況

第六章企業競爭力分析

  • 章節概述
  • 先決條件和關鍵參數
  • 調查方法
  • 學科招聘/保留服務提供商:企業競爭力分析

第 7 章公司簡介:北美學科招聘/保留服務提供商

  • 章節概述
  • Acurian
  • BBK Worldwide
  • Bright Pharmaceutical Services
  • ClinEdge
  • CSSi
  • CTM
  • Evolution Research Group (ERG)
  • Integrated Clinical Trial Services (ICTS)
  • MMG
  • Veristat
  • WCCT Global

第8章企業簡介:歐洲學科招聘/保留服務提供商

  • 章節概述
  • Antidote
  • Clinical Accelerator
  • Fidelis Research
  • Ignite Data
  • Polaris BioPharma Consulting
  • Raremark
  • Trialbee

第 9 章公司簡介:亞太學科招聘/保留服務提供商

  • 章節概述
  • Clinrol
  • CROee
  • Gitzo Medical Technology
  • Pacific Grove
  • TrialWire

第 10 章夥伴關係和協作

  • 章節概述
  • 合作模式
  • 學科招募和保留服務:夥伴關係和合作列表

第 11 章招聘和保留的最新趨勢

  • 章節概述

第12章招生對象的成長機會

  • 章節概述

第13章案例研究:招募對象的監管情況

  • 章節概述
  • 招生監管框架
  • 受試者招募相關規定

第14章以個體化醫療和罕見病為重點的臨床試驗受試者招募

  • 章節概述
  • 專注於個性化醫療和罕見病的臨床試驗

第15章臨床試驗參與者需求分析

  • 章節概述
  • 調查範圍/方法
  • 臨床試驗分析-分析:按註冊患者人群
  • 全球臨床試驗參與者的需求 - 分析:按入組患者人群
  • 結論

第16章市場規模和機會分析

  • 章節概述
  • 預測方法和主要前提
  • 整體學科招聘服務市場
  • 學科招聘服務市場-分佈:按治療區域
  • 學科招聘服務市場-分佈:按學科招聘步驟
  • 學科招聘服務市場分佈:按考試階段
  • 學科招聘服務市場-分佈:按地區

第 17 章 COVID-19 大流行對學科招聘服務市場的影響

第十八章結論

第19章採訪實錄

第20章附錄1:表格數據

第 21 章附錄 2:公司/組織名單

目錄

Title:
Patient Recruitment and Retention Services Market (2nd Edition)
by Therapeutic Areas (Cardiovascular Diseases, Oncological Disorders, Infectious Diseases, CNS Disorders, Respiratory Disorders, Hematological Disorders and Others), Patient Recruitment Steps (Pre-screening and Screening), Trial Phases (Phase I, Phase II, Phase III and Phase IV), and Key Geographies (North America, Europe, Asia-Pacific, Latin America, MENA, and RoW) - Industry Trends and Global Forecasts, 2021-2030.

Overview:

"Due to several factors, such as steady rise in global clinical trials, demand for highly specific study participants, and complex inclusion-exclusion criteria, and the challenges associated with enrolling patients in modern clinical trials, pharmaceutical companies are increasingly using the services of dedicated patient recruitment firms." - Chief Operations Officer, Israel-based Small-sized Patient Recruitment Firm.

Clinical trials are a fundamental requirement for evaluating the safety and efficacy of novel therapeutic interventions. Owing to the involvement of several different stakeholders and given the inherent complexity of the process, these trials are prone to delays, and only 10% of the pharmacological leads that are evaluated, eventually enter the market. Clinical research is also capital intensive; it is estimated that, in the US alone, 40% of the pharma R&D budget is spent on conducting clinical trials. Moreover, there are several other challenges, including inefficiencies related to data handling, and difficulties associated with patient recruitment and retention, which further complicate the investigation of new treatment options. Experts believe that the delays in product launch, caused due to inadequate recruitment, result in an average loss of USD 8 million per day, in terms of opportunity costs, for a blockbuster drug. Among the aforementioned areas of concern, patient recruitment is considered a major limiting factor with regards to the time required for a new drug to enter the market; in other words, trial durations are often extended on the grounds of insufficient enrolment. Current estimates indicate that 86% of registered clinical trials do not meet their intended planned enrolment deadlines. In additions, an estimated 37% of clinical research sites do not meet their respective subject accrual goals, while more than 10% fail to enrol even a single patient. Furthermore, retaining patients is also a major concern in pharmaceutical R&D; the approximate dropout rate (proportion of patients that are likely to leave a study before its designated end) across clinical studies conducted worldwide, is around 30%.

Over the years, patient recruitment and retention strategies have evolved significantly, especially with the availability of a variety of digital data generation, management and marketing solutions. In fact, a number of modern technology-enabled offerings are now available to support various aspects of clinical research, which include patient identification and recruitment. However, not many pharmaceutical companies have the required expertise and / or resources, to develop the necessary capabilities and effectively use the aforementioned solutions. As a result, outsourcing has become a popular operating model with regards to patient recruitment and retention; several specialty service providers, with expertise and experience in this domain, are driving the growth of this upcoming segment of the healthcare market. The advantages of engaging contract service providers are numerous and enable sponsors to meet their clinical research timelines and thereby, launch respective offerings as planned. The growing complexity of clinical trials and demand for niche patient populations for studies evaluating orphan drugs / personalized medicines, have driven many big pharma players to also outsource their patient recruitment operations and are likely to prompt more developer companies to follow suit. Recently, there has been a lot of activity within the patient recruitment and retention services market, mostly focused on consolidation of affiliated capabilities, service portfolio expansions, and collaborations to extend geographical reach. Further, considering the kind of impact the COVID-19 pandemic had on on-site activities and manual processes, we are led to believe that the patient and retention services market is likely to witness significant growth in the foreseen future.

Scope of the Report:

The 'Patient Recruitment and Retention Services Market (2nd Edition) by Therapeutic Areas (Ophthalmological Disorders, Respiratory Disorders, Dermatological Disorders, Gastrointestinal Disorders, Metabolic Disorders, CNS Disorders, Oncological Disorders, Infectious Diseases, Cardiovascular Diseases and Others), Patient Recruitment Steps (Pre-screening and Screening), Trial Phases (Phase I, Phase II, Phase III and Phase IV), and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) - Global Forecast 2021-2030' report includes an extensive study of the current scenario and future opportunities for the players providing patient enrollment and retention services. The study features an in-depth analysis, highlighting the capabilities of the various stakeholders in this domain. In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape of companies offering patient recruitment and retention services, including information on over 10 types of patient outreach methods employed, types of services offered [A] patient recruitment (including pre-screening and Institutional Review Board (IRB) / Ethics Committee (EC) submission), [B] patient retention (including various strategies, such as the use of study-branded reminders, providing education and support materials, reimbursement programs, transportation programs, study-branded gifts, patient engagement web site, mobile applications to track patient engagement, patient reconnect programs and others) and [C] other associated services (including site identification and selection, study feasibility / protocol development, project management, clinical trial monitoring and other services), year of establishment, geographical location, and size of company. The chapter also covers an analysis of the geographical reach and expertise of service providers, along with details on the payment model, patient recruitment platforms / technologies used, and the various certifications / accreditations awarded by regulatory bodies.
  • An analysis of the patient recruitment and retention activity in various regions, based on the location of companies engaged in this domain, featuring schematic world map representations that highlight the key hubs across the globe.
  • An insightful 2x2 representation of the competitiveness analysis of various service providers (segregated into three peer groups based on their employee count (small (1-200 employees), mid-sized (201-500 employees) and large / very large (>500 employees)), highlighting the top players in this domain, based on their respective capabilities.
  • Detailed profiles of patient recruitment and retention service providers, featuring information on the location of their headquarters, year of establishment, patient recruitment services / platforms portfolio, recent developments and an informed future outlook.
  • An analysis of the collaborations and partnership agreements inked in this domain since 2013; it includes details of the deals focused on patient recruitment and retention, which were analyzed on the basis of year of partnership, type of partnership (service alliances, acquisitions, patient recruitment / retention agreements, joint ventures, mergers, technology licensing agreements and others), focus area, target therapeutic area, and region. It also highlights the most active players (in terms of number of partnerships),.
  • An informed estimate of the annual demand for study participants, taking into account the target patient population in ongoing and planned clinical trials, sponsored by both industry and non-industry players.
  • A review of emerging trends in the industry, including the use of social media, mobile technologies, EHRs and RWE, to overcome the challenges associated with patient recruitment and retention.
  • A case study on regulatory landscape of patient recruitment, highlighting the regulatory process involved in patient enrollment, along with the information on regulatory guidelines, ethics committees in different countries, documents reviewed by the ethics committees (including clinical protocol, informed consent forms, investigator's brochure and participant information), ethics committee fee and review timeline.
  • A brief overview of patient recruitment in clinical trials focused on personalized medicines and rare diseases, highlighting the key challenges in patient enrollment, specialized patient outreach methods being used and the key players.
  • A detailed discussion on the upcoming trends (such as rise in the number of clinical trials, development of personalized medicine / orphan drugs, growing opportunities in emerging markets, increasing preference for one-stop solutions and others) in the field of patient recruitment and retention that are likely to impact the evolution of the market over the coming years.
  • A discussion on the likely impact of the ongoing COVID-19 pandemic on the patient recruitment and retention services market. In addition, it features various strategies that different companies have adopted / may adopt in order to mitigate the challenges associated with patient recruitment during the current global crisis.

One of the key objectives of the report was to estimate the existing market size and review the potential growth opportunities for patient recruitment service providers. Based on several parameters, we have provided an informed estimate of the likely evolution of this market in the short to mid-term and long term, for the period 2021-2030. In addition, we have segmented the future opportunity across [A] therapeutic areas (ophthalmological disorders, respiratory disorders, dermatological disorders, gastrointestinal disorders, metabolic disorders, CNS disorders, oncological disorders, infectious diseases, cardiovascular diseases and others) , [B] patient recruitment steps (pre-screening and screening), [C] trial phases (phase I, phase II, phase III and phase IV) , and [D] key geographies (North America, Europe, Asia Pacific, Middle East and Latin America, and Rest of the World). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios portraying the conservative, base and optimistic tracks of the industry's evolution.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company names),:

  • Simon Klaasen (Co-founder and Managing Director, Link2Trials)
  • Hagit Nof (Chief Operation Officer and Business Development, nRollmed)
  • Paul Ivsin (Managing Director, Seeker Health)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • Who are the leading players offering patient recruitment and retention services?
  • Which partnership models are commonly adopted by stakeholders engaged in this industry?
  • What are the key regulatory guidelines governing the patient recruitment in clinical trials, across various geographies?
  • What are the major market trends and driving factors that are likely to impact the growth of patient recruitment and retention services market?
  • How has the COVID-19 pandemic impacted the patient recruitment and retention services market?
  • How is the current and future opportunity likely to be distributed across key market segments?

Chapter Outlines:

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of the patient recruitment and retention services market and its likely evolution in the short-mid term and long term.

Chapter 3 provides a general introduction to the process of patient recruitment and retention in clinical trials. It includes a detailed discussion on the different phases of clinical trials, patient recruitment and its associated challenges, various strategies used to enhance patient accrual, affiliated ethical considerations and outsourcing activity in this domain. Further, it includes a detailed discussion on the various patient recruitment services offered by different contract service providers. Additionally, the chapter features a discussion on the patient retention strategies presently being employed to prevent enrolled participants from dropping out of clinical research studies.

Chapter 4 provides an overview of the various types of patient outreach methods used by contract service providers in this domain, to identify and enroll patients in clinical trials. The chapter also highlights the various advantages and limitations of these outreach methods.

Chapter 5 features a detailed review of the current market landscape of companies offering patient recruitment and retention services, including an in-depth analysis based on their year of establishment, geographical location, company size, type of services offered, type of patient outreach methods, geographical reach, and the therapeutic expertise of service providers. In addition, it includes details on the payment model, patient recruitment platforms / technologies used, and the various certifications / accreditations awarded to companies, by regulatory bodies from across the world.

Chapter 6 provides an insightful competitiveness analysis of patient recruitment and retention service providers that we came across during our research. The analysis compares the service providers on the basis of various parameters, such as patient outreach methods, number of patient recruitment and retention services offered, therapeutic expertise, geographical reach and year of establishment. In the chapter, stakeholder entities have been plotted on a 2x2 matrices, having a company's experience (based on its year of establishment) (abscissa) and Company Competitiveness (ordinate) as the two axes.

Chapter 7 features detailed profiles of the prominent players providing patient recruitment and retention services in North America. Each company profile includes a brief overview of the company (including information on their headquarters, year of establishment, key executives and number of employees), patient recruitment services / platforms portfolio, recent developments and an informed future outlook.

Chapter 8 features detailed profiles of the prominent players providing patient recruitment and retention services in Europe. Each company profile includes a brief overview of the company (including information on their headquarters, year of establishment, key executives and number of employees), patient recruitment services / platforms portfolio, recent developments and an informed future outlook.

Chapter 9 features detailed profiles of the prominent players providing patient recruitment and retention services in Asia Pacific. Each company profile includes a brief overview of the company (including information on their headquarters, year of establishment, key executives and number of employees), patient recruitment services / platforms portfolio, recent developments and an informed future outlook.

Chapter 10 features an analysis of the various partnerships and collaborations inked amongst players in this domain, during the time period 2013-2021 (till January). It provides a brief description on the various partnership models (service alliance, acquisition, patient recruitment / retention agreement, joint venture, merger, technology licensing agreement and other relevant types of deals) that have been adopted by stakeholders in this domain. Further, it includes analyses based on year of partnership, type of partnership, focus area, and therapeutic area, highlighting the most active players. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 11 provides a detailed overview of the prevalent trends in the patient recruitment and retention services domain, including the use of social media, mobile technologies, EHRs and RWE, to overcome the challenges associated with patient recruitment and retention in clinical research.

Chapter 12 features a detailed discussion on the upcoming opportunities (such as rise in the number of clinical trials, development of personalized medicine / orphan drugs, growing opportunities in emerging markets, increasing preference for one-stop solutions and others) in the field of patient recruitment and retention.

Chapter 13 present a case study on regulatory landscape of patient recruitment, highlighting the regulatory process involved in patient enrollment, along with the information on regulatory guidelines, ethics committees in different countries, documents reviewed by the ethics committees (including clinical protocol, informed consent forms, investigator's brochure and participant information), ethics committee fee and review timeline.

Chapter 14 features a brief overview of patient recruitment in clinical trials focused on personalized medicines and rare diseases, highlighting the key challenges in patient enrollment, specialized patient outreach methods and the key players.

Chapter 15 provides an informed estimate of the annual demand for study participants, taking into account the target patient population in ongoing and planned clinical trials, sponsored by both industry and non-industry players.

Chapter 16 presents an insightful market forecast analysis, highlighting the likely growth and future potential of patient recruitment services market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] therapeutic area (ophthalmological disorders, respiratory disorders, dermatological disorders, gastrointestinal disorders, metabolic disorders, CNS disorders, oncological disorders, infectious diseases, cardiovascular diseases and others), [B] patient recruitment step (pre-screening and screening), [C] trial phase (phase I, phase II, phase III and phase IV), and [D] key geographies (North America, Europe, Asia Pacific, Middle East and Latin America, and Rest of the World).

Chapter 17 features a discussion on the likely impact of the ongoing COVID-19 pandemic on the overall patient recruitment and retention market and the initiatives undertaken by big service providers to overcome the challenges faced due to the pandemic.

Chapter 18 is a summary of the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the patient recruitment and retention services market.

Chapter 19 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. The chapter provides details of interviews held with Simon Klaasen (Co-founder and Managing Director, Link2Trials), Hagit Nof (Chief Operation Officer and Business Development, nRollmed) and Paul Ivsin (Managing Director, Seeker Health).

Chapter 20 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 21 is an appendix, which provides the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Overview of Clinical Trials
  • 3.3. Patient Recruitment in Clinical Trials
    • 3.3.1. Challenges Associated with Patient Recruitment
    • 3.3.2. Strategies to Improve Patient Recruitment
    • 3.3.3. Ethical Considerations
  • 3.4. Outsourcing Patient Recruitment
    • 3.4.1. Patient Recruitment-related Services
  • 3.5. Patient Retention
    • 3.5.1. Patient Retention-related Services
  • 3.6. Concluding Remarks

4. PATIENT OUTREACH METHODS

  • 4.1. Chapter Overview
  • 4.2. Patient Outreach Methods
    • 4.2.1. Traditional Patient Outreach Methods
      • 4.2.1.1. Physician Referrals
      • 4.2.1.2. Television
      • 4.2.1.3. Radio
      • 4.2.1.4. Print Media (Newspaper, Flyers, Brochures and Posters)
      • 4.2.1.5. Direct Mail Campaign
      • 4.2.1.6. Cold Call / Call Centre
      • 4.2.1.7. Advantages and Limitations of Traditional Media
    • 4.2.2. Emerging Patient Outreach Methods
      • 4.2.2.1. Social Media
        • 4.2.2.1.1. Geo-Social Media
        • 4.2.2.1.2. Social Networking Websites
        • 4.2.2.1.3. Advantages and Limitations of Social Media
      • 4.2.2.2. Mobile / Software Applications
      • 4.2.2.3. Patient Networks
      • 4.2.2.4. Patient Advocacy Groups
      • 4.2.2.5. Electronic Medical Records (EMRs) / Electronic Health Records (EHRs) and Other Health Registries
      • 4.2.2.6. Search Engine Marketing / Artificial Intelligence-based Marketing
      • 4.2.2.7. Over-the-top (OTT) Media Platforms
      • 4.2.2.8. Indication Specific Events (for Patients)
    • 4.2.3. Best Practices / Recommendations for Patient Outreach

5. COMPETITIVE MARKET LANDSCAPE OF PATIENT RECRUITMENT AND RETENTION SERVICE PROVIDERS

  • 5.1. Chapter Overview
  • 5.2. Patient Recruitment and Retention Service Providers: Overall Market Landscape
    • 5.2.1. Analysis by Year of Establishment
    • 5.2.2. Analysis by Company Size
    • 5.2.3. Analysis by Location of Headquarters
    • 5.2.4. Analysis by Patient Recruitment and Retention Services Offered
    • 5.2.5. Analysis by Patient Outreach Methods
    • 5.2.6. Analysis by Patient Recruitment Associated Services
    • 5.2.7. Analysis by Patient Retention Methods
    • 5.2.8. Analysis by Geographical Reach
    • 5.2.9. Analysis by Therapeutic Expertise
    • 5.2.10. Information on Payment Model, Recruitment Technology / Platform, and Regulatory Approval / Certification / Compliance Status

6. COMPANY COMPETITIVENESS ANALYSIS

  • 6.1. Chapter Overview
  • 6.2. Assumptions and Key Parameters
  • 6.3. Methodology
  • 6.4. Patient Recruitment and Retention Service Providers: Company Competitiveness Analysis
    • 6.4.1. Competitiveness Analysis: Small Companies
    • 6.4.2. Competitiveness Analysis: Mid-Sized Companies
    • 6.4.3. Competitiveness Analysis: Large / Very Large Companies

7. COMPANY PROFILES: PATIENT RECRUITMENT AND RETENTION SERVICES PROVIDERS IN NORTH AMERICA

  • 7.1. Chapter Overview
  • 7.2. Acurian
    • 7.2.1. Company Overview
    • 7.2.2. Financial Information
    • 7.2.3. Patient Recruitment and Retention Services
    • 7.2.4. Recent Developments and Future Outlook
  • 7.3. BBK Worldwide
    • 7.3.1. Company Overview
    • 7.3.2. Financial Information
    • 7.3.3. Patient Recruitment and Retention Services
    • 7.3.4. Recent Developments and Future Outlook
  • 7.4. Bright Pharmaceutical Services
    • 7.4.1. Company Overview
    • 7.4.2. Patient Recruitment and Retention Services
    • 7.4.3. Recent Developments and Future Outlook
  • 7.5. ClinEdge
    • 7.5.1. Company Overview
    • 7.5.2. Patient Recruitment and Retention Services
    • 7.5.3. Recent Developments and Future Outlook
  • 7.6. CSSi
    • 7.6.1. Company Overview
    • 7.6.2. Patient Recruitment and Retention Services
    • 7.6.3. Recent Developments and Future Outlook
  • 7.7. CTM
    • 7.7.1. Company Overview
    • 7.7.2. Financial Information
    • 7.7.3. Patient Recruitment and Retention Services
    • 7.7.4. Recent Developments and Future Outlook
  • 7.8. Evolution Research Group (ERG)
    • 7.8.1. Company Overview
    • 7.8.2. Financial Information
    • 7.8.3. Patient Recruitment and Retention Services
    • 7.8.4. Recent Developments and Future Outlook
  • 7.9. Integrated Clinical Trial Services (ICTS)
    • 7.9.1. Company Overview
    • 7.9.2. Patient Recruitment and Retention Services
    • 7.9.3. Recent Developments and Future Outlook
  • 7.10. MMG
    • 7.10.1. Company Overview
    • 7.10.2. Patient Recruitment and Retention Services
    • 7.10.3. Recent Developments and Future Outlook
  • 7.11. Veristat
    • 7.11.1. Company Overview
    • 7.11.2. Financial Information
    • 7.11.3. Patient Recruitment and Retention Services
    • 7.11.4. Recent Developments and Future Outlook
  • 7.12. WCCT Global
    • 7.12.1. Company Overview
    • 7.12.2. Financial Information
    • 7.12.3. Patient Recruitment and Retention Services
    • 7.12.4. Recent Developments and Future Outlook

8. COMPANY PROFILES: PATIENT RECRUITMENT AND RETENTION SERVICES PROVIDERS IN EUROPE

  • 8.1. Chapter Overview
  • 8.2. Antidote
    • 8.2.1. Company Overview
    • 8.2.2. Financial Information
    • 8.2.3. Patient Requirement and Retention Services
    • 8.2.4. Recent Developments and Future Outlook
  • 8.3. Clinical Accelerator
    • 8.3.1. Company Overview
    • 8.3.2. Financial Information
    • 8.3.3. Patient Recruitment and Retention Services
    • 8.3.4. Recent Developments and Future Outlook
  • 8.4. Fidelis Research
    • 8.4.1. Company Overview
    • 8.4.2. Financial Information
    • 8.4.3. Patient Recruitment and Retention Services
    • 8.4.4. Recent Developments and Future Outlook
  • 8.5. Ignite Data
    • 8.5.1. Company Overview
    • 8.5.2. Financial Information
    • 8.5.3. Patient Recruitment and Patient Retention
    • 8.5.4. Recent Developments and Future Outlook
  • 8.6. Polaris BioPharma Consulting
    • 8.6.1. Company Overview
    • 8.6.2. Financial Information
    • 8.6.3. Patient Recruitment and Retention Services
    • 8.6.4. Recent Developments and Future Outlook
  • 8.7. Raremark
    • 8.7.1. Company Overview
    • 8.7.2. Financial Information
    • 8.7.3. Patient Recruitment and Retention Services
    • 8.7.4. Recent Developments and Future Outlook
  • 8.8. Trialbee
    • 8.8.1. Company Overview
    • 8.8.2. Financial Information
    • 8.8.3. Patient Recruitment and Retention Services
    • 8.8.4. Recent Developments and Future Outlook

9. COMPANY PROFILES: PATIENT RECRUITMENT AND RETENTION SERVICES PROVIDERS IN ASIA PACIFIC

  • 9.1. Chapter Overview
  • 9.2. Clinrol
    • 9.2.1. Company Overview
    • 9.2.2. Patient Recruitment and Retention Services
    • 9.2.3. Future Outlook
  • 9.3. CROee
    • 9.3.1. Company Overview
    • 9.3.2. Patient Recruitment and Retention Services
    • 9.3.3. Recent Developments and Future Outlook
  • 9.4. Gitzo Medical Technology
    • 9.4.1. Company Overview
    • 9.4.2. Patient Recruitment and Retention Services
    • 9.4.3. Recent Developments and Future Outlook
  • 9.5. Pacific Grove
    • 9.5.1. Company Overview
    • 9.5.2. Patient Recruitment and Retention Services
    • 9.5.3. Recent Developments and Future Outlook
  • 9.6. TrialWire
    • 9.6.1. Company Overview
    • 9.6.2. Patient Recruitment and Retention Services
    • 9.6.3. Recent Developments and Future Outlook

10. PARTNERSHIPS AND COLLABORATIONS

  • 10.1. Chapter Overview
  • 10.2. Partnership Models
  • 10.3. Patient Recruitment and Retention Services: List of Partnerships and Collaborations
    • 10.3.1. Analysis by Year of Partnership
    • 10.3.2. Analysis by Type of Partnership
    • 10.3.3. Analysis by Year and Type of Partnership
    • 10.3.4. Analysis by Focus Area
    • 10.3.5. Analysis by Year of Partnership and Focus Area
    • 10.3.6. Analysis by Therapeutic Area
    • 10.3.7. Most Active Players: Analysis by Number of Partnerships
    • 10.3.8. Geographical Analysis
      • 10.3.8.1. Region-wise Distribution
      • 10.3.8.2. Country-wise Distribution

11. RECENT TRENDS IN PATIENT RECRUITMENT AND RETENTION

  • 11.1. Chapter Overview
    • 11.1.1. Campaigning on Social Media to Accelerate Patient Recruitment in Clinical Trials
    • 11.1.2. Adoption of Mobile Technologies for Patient Recruitment and Retention
    • 11.1.3. Use of EHR Data to Improve Patient Recruitment Rates
    • 11.1.4. Use of Other Real-World Data Sources to Overcome Existing Enrolment-related Challenges
    • 11.1.5. Use of Artificial Intelligence to Improve Patient Selection
    • 11.1.6. Increase in Adoption of the Virtual Trial Model During the COVID-19 Pandemic
    • 11.1.7. Growing Focus on Conducting Clinical Research in Emerging Markets

12. FUTURE GROWTH OPPORTUNITIES IN PATIENT RECRUITMENT

  • 12.1. Chapter Overview
    • 12.1.1. Continuous Rise in the Number of Global Clinical Trials
    • 12.1.2. Rising Demand for Orphan Drugs and Personalized Medicine
    • 12.1.3. Increase in Offshoring Clinical Development Activity to Emerging Regions
    • 12.1.4. Availability of Service Providers Offering One-Stop-Solutions
    • 12.1.5. Stringent Regulations and Complex Study Protocols Prompting More Outsourcing
    • 12.1.6. Impact of the COVID-19 Pandemic on Clinical Research Activity
    • 12.1.7. Technological Advances in Clinical Trial Conduct

13. CASE STUDY: REGULATORY LANDSCAPE OF PATIENT RECRUITMENT

  • 13.1. Chapter Overview
  • 13.2. Regulatory Framework of Patient Recruitment
  • 13.3. Regulations Involved in Patient Recruitment
    • 13.3.1. ICH-GCP Guidelines
    • 13.3.2. Declaration of Helsinki
    • 13.3.3. General Data Privacy Regulation (GDPR)
    • 13.3.4. Health Insurance Portability and Accountability Act (HIPAA)

14. PATIENT RECRUITMENT IN TRIALS FOCUSED ON PERSONALIZED MEDICINE AND RARE DISEASES

  • 14.1. Chapter Overview
  • 14.2. Clinical Trials Focused on Personalized Medicine and Rare Diseases
    • 14.2.1. Key Challenges
    • 14.2.2. Specialized Patient Outreach Methods
    • 14.2.3. Key Players

15. ANALYSIS OF DEMAND FOR CLINICAL TRIAL PARTICIPANTS

  • 15.1. Chapter Overview
  • 15.2. Scope and Methodology
  • 15.3. Clinical Trial Analysis: Analysis by Enrolled Patient Population
    • 15.3.1. Analysis by Trial Registration Year
    • 15.3.2. Analysis by Trial Phase
    • 15.3.3. Analysis by Trial Registration Year and Trial Phase
    • 15.3.4. Analysis by Target Patient Segment
    • 15.3.5. Analysis by Trial Registration Year and Target Patient Segment
  • 15.4. Global Demand for Clinical Trial Participants: Analysis by Enrolled Patient Population
    • 15.4.1. Demand by Trial Phase
    • 15.4.2. Demand by Therapeutic Area
    • 15.4.3. Geographical Demand by Enrolled Patient Population
  • 15.5. Concluding Remarks

16. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 16.1. Chapter Overview
  • 16.2. Forecast Methodology and Key Assumptions
  • 16.3. Overall Patient Recruitment Services Market, 2021-2030
  • 16.4. Patient Recruitment Services Market, 2021-2030: Distribution by Therapeutic Area
  • 16.5. Patient Recruitment Services Market, 2021-2030: Distribution by Patient Recruitment Steps
  • 16.6. Patient Recruitment Services Market, 2021-2030: Distribution by Trial Phase
  • 16.7. Patient Recruitment Services Market, 2021-2030: Distribution by Geography
    • 16.7.1. Patient Recruitment Services Market, 2021-2030: Market Attractiveness Analysis by Country
    • 16.7.2. Patient Recruitment Services Market in North America, 2021-2030
      • 16.7.2.1. Patient Recruitment Services Market in the US, 2021-2030: Distribution by Trial Phase
      • 16.7.2.2. Patient Recruitment Services Market in the US, 2021-2030: Distribution by Therapeutic Area
      • 16.7.2.3. Patient Recruitment Services Market in Canada, 2021-2030: Distribution by Trial Phase
      • 16.7.2.4. Patient Recruitment Services Market in Canada, 2021-2030: Distribution by Therapeutic Area
    • 16.7.3. Patient Recruitment Services Market in Europe, 2021-2030
      • 16.7.3.1. Patient Recruitment Services Market in Germany, 2021-2030: Distribution by Trial Phase
      • 16.7.3.2. Patient Recruitment Services Market in Germany, 2021-2030: Distribution by Therapeutic Area
      • 16.7.3.3. Patient Recruitment Services Market in France, 2021-2030: Distribution by Trial Phase
      • 16.7.3.4. Patient Recruitment Services Market in France, 2021-2030: Distribution by Therapeutic Area
      • 16.7.3.5. Patient Recruitment Services Market in the UK, 2021-2030: Distribution by Trial Phase
      • 16.7.3.6. Patient Recruitment Services Market in the UK, 2021-2030: Distribution by Therapeutic Area
      • 16.7.3.7. Patient Recruitment Services Market in Italy, 2021-2030: Distribution by Trial Phase
      • 16.7.3.8. Patient Recruitment Services Market in Italy, 2021-2030: Distribution by Therapeutic Area
      • 16.7.3.9. Patient Recruitment Services Market in Spain, 2021-2030: Distribution by Trial Phase
      • 16.7.3.10. Patient Recruitment Services Market in Spain, 2021-2030: Distribution by Therapeutic Area
      • 16.7.3.11. Patient Recruitment Services Market in Rest of Europe, 2021-2030: Distribution by Trial Phase
      • 16.7.3.12. Patient Recruitment Services Market in Rest of Europe, 2021-2030: Distribution by Therapeutic Area
    • 16.7.4. Patient Recruitment Services Market in Asia Pacific, 2021-2030
      • 16.7.4.1. Patient Recruitment Services Market in Japan, 2021-2030: Distribution by Trial Phase
      • 16.7.4.2. Patient Recruitment Services Market in Japan, 2021-2030: Distribution by Therapeutic Area
      • 16.7.4.3. Patient Recruitment Services Market in South Korea, 2021-2030: Distribution by Trial Phase
      • 16.7.4.4. Patient Recruitment Services Market in South Korea, 2021-2030: Distribution by Therapeutic Area
      • 16.7.4.5. Patient Recruitment Services Market in Australia, 2021-2030: Distribution by Trial Phase
      • 16.7.4.6. Patient Recruitment Services Market in Australia, 2021-2030: Distribution by Therapeutic Area
      • 16.7.4.7. Patient Recruitment Services Market in China, 2021-2030: Distribution by Trial Phase
      • 16.7.4.8. Patient Recruitment Services Market in China, 2021-2030: Distribution by Therapeutic Area
      • 16.7.4.9. Patient Recruitment Services Market in India, 2021-2030: Distribution by Trial Phase
      • 16.7.4.10. Patient Recruitment Services Market in India, 2021-2030: Distribution by Therapeutic Area
    • 16.7.5 Patient Recruitment Services Market in Latin America, 2021-2030
      • 16.7.5.1. Patient Recruitment Services Market in Latin America, 2021-2030: Distribution by Trial Phase
      • 16.7.5.2. Patient Recruitment Services Market in Latin America, 2021-2030: Distribution by Therapeutic Area
    • 16.7.6. Patient Recruitment Services Market in MENA, 2021-2030
      • 16.7.6.1. Patient Recruitment Services Market in MENA, 2021-2030: Distribution by Trial Phase
      • 16.7.6.2. Patient Recruitment Services Market in MENA, 2021-2030: Distribution by Therapeutic Area
    • 16.7.7. Patient Recruitment Services Market in Rest of the World, 2021-2030
      • 16.7.7.1. Patient Recruitment Services Market in Rest of the World, 2021-2030: Distribution by Trial Phase
      • 16.7.7.2. Patient Recruitment Services Market in Rest of the World, 2021-2030: Distribution by Therapeutic Area

17. IMPACT OF THE COVID-19 PANDEMIC ON PATIENT RECRUITMENT SERVICES MARKET

  • 17.1. Chapter Overview
  • 17.2. Impact of COVID-19 Pandemic on Clinical Trials
    • 17.2.1. Impact on Future Opportunity Related to Patient Recruitment Services
    • 17.2.2. Initiatives Undertaken by Key Patient Recruitment and Retention Service Providers
      • 17.2.2.1. Trialspark
      • 17.2.2.2. BBK Worldwide
      • 17.2.2.3. Clariness
      • 17.2.2.4. CSSi
      • 17.2.2.5. IQVIA
  • 17.3. Key Strategies to Mitigate Challenges Associated with Patient Recruitment and Retention

18. CONCLUDING REMARKS

19. INTERVIEW TRANSCRIPTS

  • 19.1. Chapter Overview
  • 19.2. Link2Trials
    • 19.2.1. Company Snapshot
    • 19.2.2. Interview Transcript: Simon Klaasen, Co-founder and Managing Director
  • 19.3. nRollmed
    • 19.3.1. Company Snapshot
    • 19.3.2. Interview Transcript: Hagit Nof, Chief Operation Officer and Business Development Officer
  • 19.4. Seeker Health
    • 19.4.1. Company Snapshot
    • 19.4.2. Interview Transcript: Paul Ivsin, Managing Director

20. APPENDIX 1: TABULATED DATA

21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

  • Figure 3.1 Factors Contributing to Clinical Trial Cost
  • Figure 3.2 The Patient Recruitment Process
  • Figure 3.3 Factors Influencing Participation in Clinical Trials
  • Figure 3.4 Reasons for Patient Dropouts from Clinical Studies
  • Figure 4.1 Patient Outreach: Advantages and Limitations of Traditional Patient Outreach Methods
  • Figure 4.2 Patient Outreach: Advantages and Limitations of Social Media
  • Figure 5.1 Patient Recruitment and Retention Service Providers: Distribution by Year of Establishment
  • Figure 5.2 Patient Recruitment and Retention Service Providers: Distribution by Company Size
  • Figure 5.3 Patient Recruitment and Retention Service Providers: Distribution by Location of Headquarters
  • Figure 5.4 Patient Recruitment and Retention Service Providers: Distribution by Company Size and Location of Headquarters
  • Figure 5.5 Patient Recruitment and Retention Service Providers: Distribution by Type of Service(s) Offered
  • Figure 5.6 Patient Recruitment and Retention Service Providers: Distribution by Type of Patient Outreach Method(s)
  • Figure 5.7 Patient Recruitment and Retention Service Providers: Distribution by Number of Patient Outreach Methods Offered
  • Figure 5.8 Patient Recruitment and Retention Service Providers: Distribution by Patient Recruitment Associated Service(s) Offered
  • Figure 5.9 Patient Recruitment and Retention Service Providers: Distribution by Number of Patient Recruitment Associated Services Offered
  • Figure 5.10 Patient Recruitment and Retention Service Providers: Distribution by Patient Retention Method(s) Used
  • Figure 5.11 Patient Recruitment and Retention Service Providers: Distribution by Number of Patient Retention Methods
  • Figure 5.12 Patient Recruitment and Retention Service Providers: Distribution by Geographical Reach
  • Figure 5.13 Patient Recruitment and Retention Service Providers: Distribution by Therapeutic Expertise
  • Figure 6.1 Company Competitiveness Analysis: Small Players
  • Figure 6.2 Company Competitiveness Analysis: Mid-Sized Players
  • Figure 6.3 Company Competitiveness Analysis: Large / Very Large Players
  • Figure 7.1 Acurian: Innovative Tools / Approaches for Patient Enrollment
  • Figure 7.2 BBK Worldwide: Service Portfolio
  • Figure 7.3 Bright Pharmaceutical Services: Service Portfolio
  • Figure 7.4 ClinEdge: Service Portfolio
  • Figure 7.5 CSSi: Patient Recruitment and Retention Capabilities
  • Figure 7.6 CSSi: Study Branding Strategies
  • Figure 7.7 CTM: Patient Recruitment Process
  • Figure 7.8 CTM: Outreach Methods Used for Patient Recruitment
  • Figure 7.9 CTM: Technologies Used for Patient Recruitment and Retention
  • Figure 8.1 Antidote: Service Portfolio
  • Figure 8.2 Antidote Base: Patient Recruitment Process
  • Figure 8.3 Clinical Accelerator: Service Portfolio
  • Figure 8.4 FIDELIS RESEARCH: Service Portfolio
  • Figure 8.5 Ignite Data: Patient Recruitment and Call-Screening Process
  • Figure 8.6 Ignite Data: Patient Recruitment Strategies
  • Figure 8.7 Polaris BioPharma Consulting: Core Capabilities
  • Figure 8.8 Polaris BioPharma Consulting: Service Portfolio
  • Figure 8.9 Raremark: Service Portfolio
  • Figure 8.10 Raremark: Local Support Divisions
  • Figure 8.11 Trialbee: Patient Recruitment Process
  • Figure 9.1 Clinrol: Patient Recruitment Process
  • Figure 9.2 CROee: Service Portfolio
  • Figure 9.3 Pacific Grove: Business Divisions
  • Figure 9.4 Pacific Grove: Patient Enrollment Process
  • Figure 9.5 TrialWire: Patient Recruitment Process
  • Figure 9.6 TrialWire: Rapid Recruit Platform
  • Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Distribution, 2013-2021 (till January)
  • Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2013-2021 (till January)
  • Figure 10.4 Partnerships and Collaborations: Distribution by Focus Area
  • Figure 10.5 Partnerships and Collaborations: Distribution by Year of Partnership and Focus Area
  • Figure 10.6 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Figure 10.7 Most Active Players: Analysis by Number of Partnerships
  • Figure 10.8 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Figure 10.9 Partnerships and Collaborations: Country-wise Distribution
  • Figure 11.1 Recent Trends in Patient Recruitment and Retention
  • Figure 12.1 Patient Recruitment Services Market: Future Growth Opportunities
  • Figure 12.2 Number of Global Clinical Trials Registered by Year, 2000-2020
  • Figure 12.3 Evolution of Clinical Trial Regulations in the US
  • Figure 13.1 Patient Recruitment Regulatory Pathway
  • Figure 13.2 Regulatory Guidelines Involved in Patient Recruitment
  • Figure 14.1 Key Challenges in Patient Enrollment in Trials Focused on Personalized Medicines
  • Figure 14.2 Key Challenges in Patient Enrollment in Trials Focused on Rare Diseases
  • Figure 14.3 Specialized Patient Outreach Methods
  • Figure 15.1 Clinical Trial Analysis: Distribution by Trial Registration Year
  • Figure 15.2 Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 15.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase
  • Figure 15.4 Clinical Trial Analysis: Distribution by Target Patient Segment
  • Figure 15.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Target Patient Segment
  • Figure 15.6 Global Demand for Clinical Trial Participants: Distribution by Trial Phase
  • Figure 15.7 Global Demand for Clinical Trial Participants: Distribution by Therapeutic Area
  • Figure 15.8 Global Demand for Clinical Trial Participants: Distribution by Region
  • Figure 16.1 Overall Patient Recruitment Services Market, 2021-2030 (USD Billion)
  • Figure 16.2 Patient Recruitment Services Market, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 16.3 Patient Recruitment Services Market, 2021-2030: Distribution by Patient Recruitment Steps (USD Million)
  • Figure 16.4 Patient Recruitment Services Market, 2021-2030: Distribution by Trial Phase (USD Million)
  • Figure 16.5 Patient Recruitment Services Market, 2021-2030: Distribution by Geography (USD Million)
  • Figure 16.6 Patient Recruitment Services Market, 2021 and 2030: Market Attractiveness Analysis by Country
  • Figure 16.7 Patient Recruitment Services Market in North America, 2021-2030 (USD Million)
  • Figure 16.8 Patient Recruitment Services Market in the US, 2021-2030: Distribution by Trial Phase (USD Million)
  • Figure 16.9 Patient Recruitment Services Market in the US, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 16.10 Patient Recruitment Services Market in Canada, 2021-2030: Distribution by Trial Phase (USD Million)
  • Figure 16.11 Patient Recruitment Services Market in Canada, 2021-2030: Distribution by Therapeutic Area (USD Billion)
  • Figure 16.12 Patient Recruitment Services Market in Europe, 2021-2030 (USD Million)
  • Figure 16.13 Patient Recruitment Services Market in Germany, 2021-2030: Distribution by Trial Phase (USD Million)
  • Figure 16.14 Patient Recruitment Services Market in Germany, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 16.15 Patient Recruitment Services Market in France, 2021-2030: Distribution by Trial Phase (USD Million)
  • Figure 16.16 Patient Recruitment Services Market in France, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 16.17 Patient Recruitment Services Market in the UK, 2021-2030: Distribution by Trial Phase (USD Million)
  • Figure 16.18 Patient Recruitment Services Market in the UK, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 16.19 Patient Recruitment Services Market in Italy, 2021-2030: Distribution by Trial Phase (USD Million)
  • Figure 16.20 Patient Recruitment Services Market in Italy, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 16.21 Patient Recruitment Services Market in Spain, 2021-2030: Distribution by Trial Phase (USD Million)
  • Figure 16.22 Patient Recruitment Services Market in Spain, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 16.23 Patient Recruitment Services Market in Rest of Europe, 2021-2030: Distribution by Trial Phase (USD Million)
  • Figure 16.24 Patient Recruitment Services Market in Rest of Europe, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 16.25 Patient Recruitment Services Market in Asia Pacific, 2021-2030 (USD Million)
  • Figure 16.26 Patient Recruitment Services Market in Japan, 2021-2030: Distribution by Trial Phase (USD Million)
  • Figure 16.27 Patient Recruitment Services Market in Japan, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 16.28 Patient Recruitment Services Market in South Korea, 2021-2030: Distribution by Trial Phase (USD Million)
  • Figure 16.29 Patient Recruitment Services Market in South Korea, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 16.30 Patient Recruitment Services Market in Australia, 2021-2030: Distribution by Trial Phase (USD Million)
  • Figure 16.31 Patient Recruitment Services Market in Australia, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 16.32 Patient Recruitment Services Market in China, 2021-2030: Distribution by Trial Phase (USD Million)
  • Figure 16.33 Patient Recruitment Services Market in China, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 16.34 Patient Recruitment Services Market in India, 2021-2030: Distribution by Trial Phase (USD Million)
  • Figure 16.35 Patient Recruitment Services Market in India, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 16.36 Patient Recruitment Services Market in Latin America, 2021-2030 (USD Million)
  • Figure 16.37 Patient Recruitment Services Market in Latin America, 2021-2030: Distribution by Trial Phase (USD Million)
  • Figure 16.38 Patient Recruitment Services Market in Latin America, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 16.39 Patient Recruitment Services Market in MENA, 2021-2030 (USD Million)
  • Figure 16.40 Patient Recruitment Services Market in MENA, 2021-2030: Distribution by Trial Phase (USD Million)
  • Figure 16.41 Patient Recruitment Services Market in MENA, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 16.42 Patient Recruitment Services Market in Rest of the World, 2021-2030 (USD Million)
  • Figure 16.43 Patient Recruitment Services Market in Rest of the World, 2021-2030: Distribution by Trial Phase (USD Million)
  • Figure 16.44 Patient Recruitment Services Market in Rest of the World, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 17.1 Patient Recruitment Services Market, 2021-2030: COVID Impact Scenario (USD Billion)
  • Figure 18.1 Concluding Remarks: Overall Market Landscape

List Of Tables

  • Table 3.1 Characteristic Features of Clinical Trial Phases
  • Table 4.1 Traditional and Emerging Patient Outreach Methods
  • Table 5.1 List of Patient Recruitment and Retention Service Providers
  • Table 5.2 Patient Recruitment and Retention Service Providers: Information on Patient Outreach Methods
  • Table 5.3 Patient Recruitment and Retention Service Providers: Information on Type of Patient Recruitment Service(s) Offered
  • Table 5.4 Patient Recruitment and Retention Service Providers: Information on Patient Retention Method(s) Used
  • Table 5.5 Patient Recruitment and Retention Service Providers: Information on Geographical Reach
  • Table 5.6 Patient Recruitment and Retention Service Providers: Information on Therapeutic Expertise
  • Table 5.7 Patient Recruitment and Retention Service Providers: Information on Payment Model, Recruitment Technology / Platform, and Regulatory Approval / Certification / Compliance Status
  • Table 7.1 Leading Patient Recruitment Service Providers in North America
  • Table 7.2 Acurian: Company Overview
  • Table 7.3 Acurian: Recent Developments and Future Outlook
  • Table 7.4 BBK Worldwide: Company Overview
  • Table 7.5 BBK Worldwide: Recent Developments and Future Outlook
  • Table 7.6 Bright Pharmaceutical Services: Company Overview
  • Table 7.7 Bright Pharmaceutical Services: Recent Developments and Future Outlook
  • Table 7.8 ClinEdge: Company Snapshot
  • Table 7.9 ClinEdge: Recent Developments and Future Outlook
  • Table 7.10 CSSi: Company Snapshot
  • Table 7.11 CSSi: Recent Developments and Future Outlook
  • Table 7.12 CTM: Company Snapshot
  • Table 7.13 CTM: Recent Developments and Future Outlook
  • Table 7.14 Evolution Research Group: Company Snapshot
  • Table 7.15 Evolution Research Group: Recent Developments and Future Outlook
  • Table 7.16 Integrated Clinical Trial Services: Company Snapshot
  • Table 7.17 Integrated Clinical Trial Services: Recent Developments and Future Outlook
  • Table 7.18 MMG: Company Snapshot
  • Table 7.19 MMG: Recent Developments and Future Outlook
  • Table 7.20 Veristat: Company Snapshot
  • Table 7.21 Veristat: Recent Developments and Future Outlook
  • Table 7.22 WCCT Global: Company Snapshot
  • Table 7.23 WCCT Global: Recent Developments and Future Outlook
  • Table 8.1 Leading Patient Recruitment Service Providers in Europe
  • Table 8.2 Antidote: Company Snapshot
  • Table 8.3 Antidote: Funding
  • Table 8.4 Antidote: Recent Developments and Future Outlook
  • Table 8.5 Clinical Accelerator: Company Snapshot
  • Table 8.6 Clinical Accelerator: Recent Developments and Future Outlook
  • Table 8.7 FIDELIS RESEARCH Company Snapshot
  • Table 8.8 Fidelis Research: Recent Developments and Future Outlook
  • Table 8.9 Ignite Data: Company Snapshot
  • Table 8.10 Ignite Data: Recent Developments and Future Outlook
  • Table 8.11 Polaris BioPharma Consulting: Company Snapshot
  • Table 8.12 Polaris BioPharma Consulting: Recent Developments and Future Outlook
  • Table 8.13 Raremark: Company Snapshot
  • Table 8.14 Raremark: Recent Developments and Future Outlook
  • Table 8.15 Trialbee: Company Snapshot
  • Table 8.16 Trialbee: Funding
  • Table 8.17 Trialbee: Recent Developments and Future Outlook
  • Table 9.1 Leading Patient Recruitment Service Providers in Asia Pacific
  • Table 9.2 Clinrol: Company Snapshot
  • Table 9.3 Clinrol: Recent Developments and Future Outlook
  • Table 9.4 CROee: Company Snapshot
  • Table 9.5 CROee: Recent Developments and Future Outlook
  • Table 9.6 Gitzo Pharmaceuticals Company Snapshot
  • Table 9.7 Gitzo Pharmaceuticals : Recent Developments and Future Outlook
  • Table 9.8 Pacific Grove: Company Snapshot
  • Table 9.9 Pacific Grove: Recent Developments and Future Outlook
  • Table 9.10 TrialWire: Company Snapshot
  • Table 9.11 Trial Wire: Recent Developments and Future Outlook
  • Table 10.1 Patient Recruitment and Retention Services: Partnerships and Collaborations, 2013-2021 (till January)
  • Table 14.1 Patient Recruitment Service Providers for Trials Focused on Personalized Medicines and Rare Diseases
  • Table 19.1 Link2Trials: Company Snapshot
  • Table 19.2 nRollmed: Company Snapshot
  • Table 19.3 Seeker Health: Company Snapshot
  • Table 20.1 Patient Recruitment and Retention Service Providers: Distribution by Year of Establishment
  • Table 20.2 Patient Recruitment and Retention Service Providers: Distribution by Company Size
  • Table 20.3 Patient Recruitment and Retention Service Providers: Distribution by Location of Headquarters
  • Table 20.4 Patient Recruitment and Retention Service Providers: Distribution by Type of Service(s) Offered
  • Table 20.5 Patient Recruitment and Retention Service Providers: Distribution by Type of Patient Outreach Method(s)
  • Table 20.6 Patient Recruitment and Retention Service Providers: Distribution by Number of Patient Outreach Methods Offered
  • Table 20.7 Patient Recruitment and Retention Service Providers: Distribution by Patient Recruitment Associated Service(s) Offered
  • Table 20.8 Patient Recruitment and Retention Service Providers: Distribution by Number of Patient Recruitment Associated Services Offered
  • Table 20.9 Patient Recruitment and Retention Service Providers: Distribution by Patient Retention Method(s) Used
  • Table 20.10 Patient Recruitment and Retention Service Providers: Distribution by Number of Patient Retention Methods
  • Table 20.11 Patient Recruitment and Retention Service Providers: Distribution by Geographical Reach
  • Table 20.12 Patient Recruitment and Retention Service Providers: Distribution by Therapeutic Expertise
  • Table 20.13 Partnerships and Collaborations: Cumulative Year-wise Distribution, 2013-2021 (till January)
  • Table 20.14 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 20.15 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Table 20.16 Partnerships and Collaborations: Distribution by Focus Area
  • Table 20.17 Partnerships and Collaborations: Distribution by Year of Partnership and Focus Area
  • Table 20.18 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Table 20.19 Most Active Players: Analysis by Number of Partnerships
  • Table 20.20 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Table 20.21 Partnerships and Collaborations: Country-wise Distribution
  • Table 20.22 Clinical Trial Analysis: Distribution by Trial Registration Year
  • Table 20.23 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 20.24 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase
  • Table 20.25 Clinical Trial Analysis: Distribution by Target Patient Segment
  • Table 20.26 Clinical Trial Analysis: Distribution by Trial Registration Year and Target Patient Segment
  • Table 20.27 Global Demand for Clinical Trial Participants: Distribution by Trial Phase
  • Table 20.28 Global Demand for Clinical Trial Participants: Distribution by Therapeutic Area
  • Table 20.29 Global Demand for Clinical Trial Participants: Distribution by Region
  • Table 20.30 Overall Patient Recruitment Services Market, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 20.31 Patient Recruitment Services Market, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 20.32 Patient Recruitment Services Market, 2021-2030: Distribution by Patient Recruitment Steps (USD Million)
  • Table 20.33 Patient Recruitment Services Market, 2021-2030: Distribution by Trial Phase, (USD Million)
  • Table 20.34 Patient Recruitment Services Market, 2021-2030: Distribution by Geography (USD Million)
  • Table 20.35 Patient Recruitment Services Market, 2021 and 2030: Market Attractiveness Analysis by Country
  • Table 20.36 Patient Recruitment Services Market in North America, 2021-2030, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 20.37 Patient Recruitment Services Market in the US, 2021-2030: Distribution by Trial Phase (USD Million)
  • Table 20.38 Patient Recruitment Services Market in the US, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 20.39 Patient Recruitment Services Market in Canada, 2021-2030: Distribution by Trial Phase (USD Million)
  • Table 20.40 Patient Recruitment Services Market in Canada, 2021-2030: Distribution by Therapeutic Area (USD Billion)
  • Table 20.41 Patient Recruitment Services Market in Europe, 2021-2030, Conservative, Base and Optimistic Scenario, (USD Million)
  • Table 20.42 Patient Recruitment Services Market in Germany, 2021-2030: Distribution by Trial Phase (USD Million)
  • Table 20.43 Patient Recruitment Services Market in Germany, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 20.44 Patient Recruitment Services Market in France, 2021-2030: Distribution by Trial Phase (USD Million)
  • Table 20.45 Patient Recruitment Services Market in France, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 20.46 Patient Recruitment Services Market in the UK, 2021-2030: Distribution by Trial Phase (USD Million)
  • Table 20.47 Patient Recruitment Services Market in the UK, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 20.48 Patient Recruitment Services Market in Italy, 2021-2030: Distribution by Trial Phase (USD Million)
  • Table 20.49 Patient Recruitment Services Market in Italy, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 20.50 Patient Recruitment Services Market in Spain, 2021-2030: Distribution by Trial Phase (USD Million)
  • Table 20.51 Patient Recruitment Services Market in Spain, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 20.52 Patient Recruitment Services Market in Rest of Europe, 2021-2030: Distribution by Trial Phase (USD Million)
  • Table 20.53 Patient Recruitment Services Market in Rest of Europe, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 20.54 Patient Recruitment Services Market in Asia Pacific, 2021-2030, Conservative, Base and Optimistic Scenario, (USD Million)
  • Table 20.55 Patient Recruitment Services Market in Japan, 2021-2030: Distribution by Trial Phase (USD Million)
  • Table 20.56 Patient Recruitment Services Market in Japan, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 20.57 Patient Recruitment Services Market in South Korea, 2021-2030: Distribution by Trial Phase (USD Million)
  • Table 20.58 Patient Recruitment Services Market in South Korea, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 20.59 Patient Recruitment Services Market in Australia, 2021-2030: Distribution by Trial Phase (USD Million)
  • Table 20.60 Patient Recruitment Services Market in Australia, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 20.61 Patient Recruitment Services Market in China, 2021-2030: Distribution by Trial Phase (USD Million)
  • Table 20.62 Patient Recruitment Services Market in China, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 20.63 Patient Recruitment Services Market in India, 2021-2030: Distribution by Trial Phase (USD Million)
  • Table 20.64 Patient Recruitment Services Market in India, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 20.65 Patient Recruitment Services Market in Latin America, 2021-2030, Conservative, Base and Optimistic Scenario, (USD Million)
  • Table 20.66 Patient Recruitment Services Market in Latin America, 2021-2030: Distribution by Trial Phase (USD Million)
  • Table 20.67 Patient Recruitment Services Market in Latin America, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 20.68 Patient Recruitment Services Market in MENA, 2021-2030, Conservative, Base and Optimistic Scenario, (USD Million)
  • Table 20.69 Patient Recruitment Services Market in MENA, 2021-2030: Distribution by Trial Phase (USD Million)
  • Table 20.70 Patient Recruitment Services Market in MENA, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 20.71 Patient Recruitment Services Market in Rest of the World, 2021-2030, Conservative, Base and Optimistic Scenario, (USD Million)
  • Table 20.72 Patient Recruitment Services Market in Rest of the World, 2021-2030: Distribution by Trial Phase (USD Million)
  • Table 20.73 Patient Recruitment Services Market in Rest of the World, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 20.74 Patient Recruitment Services Market, 2021-2030: COVID Impact Scenario (USD Billion)

List Of Companies

The following companies and organizations have been mentioned in this report.

  • 1. 23andMe
  • 2. 3H Medi Solution
  • 3. Abnex
  • 4. Academic Network
  • 5. Accel Trial Connections Network
  • 6. Access Clinical Research
  • 7. Accurate Clinical Research
  • 8. Acurian
  • 9. Addario Lung Cancer Foundation
  • 10. Addario Lung Cancer Medical Institute
  • 11. Adult Medicine
  • 12. Advanced Clinical
  • 13. AiCure
  • 14. Alkemy Partners
  • 15. Alleco Research
  • 16. Alliance Community Healthcare
  • 17. Allscripts
  • 18. American Liver Foundation
  • 19. American Society of Clinical Oncology
  • 20. Amgen
  • 21. Anteris Bio
  • 22. Antidote
  • 23. ApotheCom
  • 24. Apptomics
  • 25. AQLANE Medical
  • 26. Arden and Schmidt
  • 27. AstraZeneca
  • 28. ATLAS Medical Services
  • 29. AutoCruitment
  • 30. AXELLE Group
  • 31. Axiom Accelerated Patient Recruitment
  • 32. BBK Worldwide
  • 33. BIAPharm
  • 34. Bioclinica
  • 35. BIOMAPAS
  • 36. Bio-Optronics
  • 37. BioScript Solutions
  • 38. Blue Chip Patient Recruitment (BCPR)
  • 39. Blueprint Clinical
  • 40. BlueTheory Clinical Trials
  • 41. BMC Group
  • 42. Box
  • 43. Bridge Clinical Research
  • 44. Bright Pharmaceutical Services
  • 45. Buzzreach
  • 46. C & C Clinical
  • 47. Canadian Institute for Medical Advancement (CIMA)
  • 48. Capsule Communications
  • 49. CaringKind
  • 50. CarthagoPharma
  • 51. CCBR-SYNARC
  • 52. CCT Research
  • 53. Center for Women Health
  • 54. Center Point Clinical Services
  • 55. Centricity Health
  • 56. Chandler Chicco Agency (CCA)
  • 57. Chase Medical Research
  • 58. Cinven
  • 59. Circuit Clinical
  • 60. Clariness
  • 61. Clinart MENA
  • 62. ClinEdge
  • 63. Clinerion
  • 64. Clinical Accelerator
  • 65. Clinical Ambassador
  • 66. Clinical List America
  • 67. Clinical Trial
  • 68. Clinical Trial Connect (CTC)
  • 69. Clinical Trial Marketing Communications (CTMC)
  • 70. Clinical Trial Networking (CT-N)
  • 71. Clinical Trials Center
  • 72. ClinicalConnection
  • 73. Clinically Media
  • 74. ClinIntel
  • 75. CliniSpan Health
  • 76. Clinrol
  • 77. Clinspire Research
  • 78. Clintec
  • 79. Clintract
  • 80. Clinverse
  • 81. CMX Research
  • 82. Compass Research
  • 83. Continuum Clinical
  • 84. CPS Research
  • 85. CROee
  • 86. CSSi
  • 87. CSSi LifeSciences
  • 88. CTC North
  • 89. CTM
  • 90. CUBRC
  • 91. Cytespace
  • 92. DAC Patient Recruitment Services
  • 93. Datavant
  • 94. DAVA Oncology
  • 95. Discovery Clinical Trials
  • 96. DrFirst
  • 97. Eastern Medical
  • 98. Effectus CTR
  • 99. Egeen
  • 100. Elligo Health Research
  • 101. EmergingMed
  • 102. eNre
  • 103. ePatientFinder
  • 104. eStudySite
  • 105. European Organisation for Research and Treatment of Cancer (EORTC)
  • 106. EVERSANA
  • 107. Evolution Research Group
  • 108. Evrima Technologies
  • 109. FDAMap
  • 110. FIDELIS RESEARCH
  • 111. Flatiron Health
  • 112. Foundation Medicine
  • 113. Friends of Cancer Research (Friends)
  • 114. Gaea
  • 115. Galen Patient Recruitment
  • 116. GCP Clinical Studies
  • 117. Genentech
  • 118. Gitzo Pharmaceuticals
  • 119. Global Clinical Trials
  • 120. Global Perspectives
  • 121. Greater Gift
  • 122. Guidestar Research
  • 123. HCXP
  • 124. Healthcare Communications Group
  • 125. Healthjump
  • 126. HealthStar Physicians
  • 127. HealthVerity
  • 128. Heron Therapeutics
  • 129. Ignite Data
  • 130. Illingworth Research Group
  • 131. IMS Health
  • 132. Innovaderm Research
  • 133. Innovative Trials
  • 134. Inspire
  • 135. Institute of Clinical Research in India (ICRI)
  • 136. Integrated Clinical Trial Services (ICTS)
  • 137. Invicro
  • 138. iPatientAxis
  • 139. IQVIA
  • 140. IRM
  • 141. IVR Clinical Concepts
  • 142. IZI Medical
  • 143. J Trotter Research & Consulting (JTRC)
  • 144. Jack Nathan Health
  • 145. JLL Partners
  • 146. Klick Health
  • 147. Komplett Clinical Research
  • 148. LabCorp Diagnostics
  • 149. Latium Enterprises
  • 150. LeadSlinger
  • 151. Limbix
  • 152. Linden Capital Partners
  • 153. Linical
  • 154. Linical Americas
  • 155. Link2Trials
  • 156. LiveRamp
  • 157. Lyft
  • 158. Medical Research South
  • 159. Medici Group
  • 160. Medidata
  • 161. Melanoma Research Alliance
  • 162. Miami Research Associates
  • 163. MMG
  • 164. Mondosano
  • 165. Mundipharma Research
  • 166. Muscular Dystrophy Association (MDA)
  • 167. National Cancer Institute
  • 168. Newton Clinical Research
  • 169. Noom
  • 170. Northumbria Healthcare
  • 171. nRollmed
  • 172. O4 Research
  • 173. One Research
  • 174. OptimizeRx
  • 175. Orphan Reach
  • 176. Orphanos
  • 177. Osaka International Cancer Institute
  • 178. Pacific Grove
  • 179. Panacea Patient Recruitment
  • 180. Parallel 6
  • 181. Parexel
  • 182. Patient Enrollment Advisors
  • 183. PatientPoint
  • 184. Patient RM
  • 185. PatientCentra
  • 186. PatientEvolution
  • 187. Patients Direct
  • 188. Patiro
  • 189. Pepgra
  • 190. Pfizer
  • 191. PharmaCentra
  • 192. Pharmaceutical Product Development (PPD)
  • 193. Pharm-Olam
  • 194. phaware.global
  • 195. Pivotal Patient Journey,
  • 196. Polaris Biopharma Consulting
  • 197. Practice Fusion
  • 198. Praxis Communications
  • 199. PRC Clinical
  • 200. Profil
  • 201. Prominis Medical Services
  • 202. Protenium Clinical Research
  • 203. PWNHealth
  • 204. QPS
  • 205. Radiant Research
  • 206. Raremark
  • 207. RealTime Software Solutions
  • 208. Red Maple Trials
  • 209. RemediumOne
  • 210. Remedy Health Media
  • 211. Rep Network
  • 212. RESolutions
  • 213. Richmond Pharmacology
  • 214. Riverside Medical Group
  • 215. Roche
  • 216. Roswell Park Comprehensive Cancer Center
  • 217. S4 Research
  • 218. Sanguine Biosciences
  • 219. Seeker Health
  • 220. Signify Health
  • 221. Sinque Labs
  • 222. SitePartner
  • 223. SMO Clinical Research (SMO-India)
  • 224. SMO Clinplus
  • 225. Society for Clinical Research Sites
  • 226. Spectrum Clinical Research
  • 227. Splash Clinical
  • 228. STARR Coalition
  • 229. SubjectWell
  • 230. SWOG Cancer Research
  • 231. Syneos Health
  • 232. Synexus
  • 233. TFS
  • 234. The Christie NHS Foundation Trust
  • 235. The Foundation for the National Institutes of Health (FNIH)
  • 236. The Patient Recruiting Agency (TPRA)
  • 237. Patient Recruitment Consultancy
  • 238. ThreeWire
  • 239. Topstone Research
  • 240. Total Clinical Trial Management
  • 241. TrialBee
  • 242. Trialfacts
  • 243. TrialJoin
  • 244. TrialSpark
  • 245. TrialWire
  • 246. TriNetX
  • 247. United BioSource
  • 248. University of Exeter
  • 249. Unnamed Pharma Company
  • 250. Velocity Clinical Research
  • 251. Veristat
  • 252. Vineti
  • 253. Viomedo
  • 254. VisibilityRx
  • 255. Vizae Clinical Trial Management
  • 256. WCCT Global
  • 257. WCG PatientWise
  • 258. Wefight
  • 259. Western Washington Medical Group
  • 260. WIRB-Copernicus Group
  • 261. WorldQuant Predictive
  • 262. Worldwide Clinical Trials
  • 263. X Factor
  • 264. Xcene Research